Atherosclerosis

Study Shows High Volume Exercise Unrelated to Progression of Coronary Artery Calcium

Retrieved on: 
水曜日, 5月 15, 2024

This new study , published in the Journal of the American Medical Association Cardiology, shows that the progression of CAC over time is not associated with leisure-time aerobic physical activity measured at baseline and follow-up.

Key Points: 
  • This new study , published in the Journal of the American Medical Association Cardiology, shows that the progression of CAC over time is not associated with leisure-time aerobic physical activity measured at baseline and follow-up.
  • Their physical activity, CAC and other clinical measurements were determined during preventive medicine visits to Cooper Clinic in Dallas, Texas.
  • Analysis of the data, which accounted for potential confounding factors, revealed that aerobic physical activity does not appear to elevate the rate of CAC progression.
  • “This study provides important new knowledge which will greatly assist in the care of Masters athletes and highly active people who have high coronary calcium scores.

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

Retrieved on: 
水曜日, 5月 15, 2024

WESTON, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for the quarter ended March 31, 2024 and provides business update.

Key Points: 
  • Initiation of preclinical study to assess Inflammasome ASC Inhibitor IC 100 for obesity-associated metabolic comorbidities scheduled to begin Q2-2024 with completion expected by year’s end.
  • WESTON, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for the quarter ended March 31, 2024 and provides business update.
  • “We are pleased to announce that ZyVersa is on track to achieve key development milestones over the next 3 quarters,” stated Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO, and President.
  • ZyVersa will need additional financing to support its continuing operations and to meet its stated milestones.

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

Retrieved on: 
水曜日, 5月 8, 2024

“PAD affects over 230 million people globally, presenting a significantly underrecognized risk of CAD,” said Dr. Frank Arko, Chief of Vascular and Endovascular Surgery at Atrium Health Sanger Heart & Vascular Institute.

Key Points: 
  • “PAD affects over 230 million people globally, presenting a significantly underrecognized risk of CAD,” said Dr. Frank Arko, Chief of Vascular and Endovascular Surgery at Atrium Health Sanger Heart & Vascular Institute.
  • “In an additional study looking at a similar patient population, we studied 170 high-risk PAD patients, where we utilized systematic FFRCT testing.
  • Remarkably, 70 percent of these patients had hemodynamically significant CAD, which is a major risk factor for cardiac complications.
  • This publication showcases the company’s continued commitment to revolutionizing patient care with innovative and scientifically validated technologies.

New Discovery Identifies “Don’t Eat Me” Protein that Allows Lyme Bacteria to Evade Body’s Immune Response

Retrieved on: 
火曜日, 5月 7, 2024

The research was conducted at Stanford University and University of California San Francisco and funded in part by Bay Area Lyme Foundation.

Key Points: 
  • The research was conducted at Stanford University and University of California San Francisco and funded in part by Bay Area Lyme Foundation.
  • This groundbreaking data posted on bioRxiv on April 30, 2024, is expected to be published in a peer-review journal in the future.
  • “One of the big mysteries of Lyme disease has been how Borrelia is able to evade and survive the immune system – and this study helps answer that question.
  • “Patients need both a robust immune response and antibiotics to eradicate an infection - antibiotics alone are not usually sufficient.

Surrey Cardiovascular Clinic and Caristo Diagnostics Launch Employee Heart Wellness and Disease Prevention Program for UK Employers

Retrieved on: 
火曜日, 4月 23, 2024

OXFORD, England and SURREY, England , April 23, 2024 /PRNewswire/ -- Surrey Cardiovascular Clinic (SCVC), Southern England's leading centre of excellence for the prevention and treatment of cardiovascular and cancer issues, has partnered with Imaging provider VCL SURREY and Caristo Diagnostics, a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.

Key Points: 
  • SCVC will provide the CaRi-Heart AI-based cardiac assessment as a central part of the organisations 's employee wellness initiative for UK employers.
  • In combination with the programme's other tests, Cari-Heart provides the ability to predict future heart attacks and atherosclerosis many years before symptoms occur.
  • We are pleased to announce our partnership with Surrey Cardiovascular Clinic and their imaging partner VCL Surrey to enhance accessibility to CaRi-Heart technology for employees throughout the UK," said Frank Cheng, CEO of Caristo Diagnostics.
  • The CaRi-Heart technology is currently in clinical use in various NHS and private hospitals in the UK, as well as within the EU and Australia.

NYU Langone Health's New Optimal Aging Institute to Further Explore the Link Between Vascular Health and Aging

Retrieved on: 
木曜日, 4月 11, 2024

NEW YORK, April 11, 2024 /PRNewswire/ -- Researchers at the newly-formed Optimal Aging Institute at NYU Langone Health have been awarded $31 million by the National Institutes of Health (NIH) for a diverse, ten university cohort to study how vascular risk factors contribute to dementia and other age-related disorders in those over the age of 85, building upon existing research.

Key Points: 
  • Close integration with partners across NYU Langone Health system, Coresh said, enables the Institute to implement and test interventions with real-world impacts in real-time, advancing practice-changing research to improve outcomes for all.
  • to highlight an important topic at the intersection of vascular health and aging.
  • The event, co-sponsored by NYU Langone's Department of Population Health and the Optimal Aging Institute, will feature six renowned experts in the field and will showcase recent groundbreaking research on how treating hypertension may prevent dementia.
  • The research is supported by The National Heart, Lung, and Blood Institute, a division of the NIH, grant number U01HL096812.

Caring for older Americans’ teeth and gums is essential, but Medicare generally doesn’t cover that cost

Retrieved on: 
金曜日, 4月 19, 2024

As dentistry scholars, we believe Koop also deserves credit for something else.

Key Points: 
  • As dentistry scholars, we believe Koop also deserves credit for something else.
  • Americans who rely on the traditional Medicare program for their health insurance get no help from that program with paying their dental bills aside from some narrow exceptions.
  • This group includes some 24 million people over 65 – about half of all the people who rely on Medicare for their health insurance.

‘Medically necessary’ exceptions

  • The list of circumstances that would lead patients to be eligible is short.
  • Some examples include patients scheduled for organ transplants or who have cancer treatment requiring radiation of their jaws.
  • But we believe that dental care is necessary for everyone, especially for older people.

Chew, speak, breathe

  • While many working Americans get limited dental coverage through their employers, those benefits are usually limited to as little as $1,000 per year.
  • And once they retire, Americans almost always lose even that basic coverage.
  • Rich Americans with Medicare coverage are almost three times more likely to receive dental care compared to those with low incomes.

Connected to many serious conditions

  • Having diabetes makes you three times as likely to develop gum disease because diabetes compromises the body’s response to inflammation and infection.
  • At the same time, treating diabetes patients for gum disease can help control their blood sugar levels.

Chemo can damage your teeth


Many cancer treatments can damage teeth, especially for older adults. As a result, Medicare has started to reimburse for dental bills tied to tooth decay or other oral conditions after they get chemotherapy or radiation treatment.

More than nice to have

  • Doctors and dentists are educated separately, and doctors learn very little about dental conditions and treatments when they’re in medical school.
  • Most dental electronic health records aren’t linked to medical systems, hindering comprehensive care and delivery of dental care to those in need.
  • Medical insurance was designed specifically to cover large, unpredictable expenses, while dental insurance was intended to mainly fund predictable and lower-cost preventive care.

Medicare Advantage plans

  • Until Medicare expands coverage to include preventive dental services for everyone, alternative plans such as Medicare Advantage, through which the federal government contracts with private insurers to provide Medicare benefits, serve as a stopgap.
  • In 2016, only 21% of beneficiaries in traditional Medicare had purchased a stand-alone dental plan, whereas roughly two-thirds of Medicare Advantage enrollees had at least some dental benefits through their coverage.


Frank Scannapieco is affiliated with The Task Force on Design and Analysis in Oral Health Research, and consults for the Colgate-Palmolive Company. Ira Lamster is a member of the Santa Fe Group. He currently receives consulting fees from Colgate, and research support from the CareQuest Institute.

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
日曜日, 4月 7, 2024

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
月曜日, 3月 25, 2024

WESTON, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for full year ending December 31, 2023, and provides business update.

Key Points: 
  • Scientific collaboration to assess Inflammasome ASC Inhibitor IC 100 as a potential treatment for atherosclerosis expected to conclude H1-2024.
  • WESTON, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for full year ending December 31, 2023, and provides business update.
  • “Throughout 2023 and early 2024, ZyVersa achieved considerable progress in advancing development of our two lead candidates.
  • The impairment is a result of the decline in stock value and the resulting market capitalization of ZyVersa during the 2023 Period.

Merit Medical Launches the Micro ACE™ Advanced Micro-Access System

Retrieved on: 
火曜日, 3月 19, 2024

SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System.

Key Points: 
  • SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System.
  • Merit also intends to file Micro ACE for CE mark designation.
  • The Micro ACE system is the latest innovation in the Merit Vascular portfolio.
  • Combining a balance of stiffness and resiliency, Micro ACE is designed to achieve micro-access in a wide range of vascular anatomies.